Galvin Gaustad & Stein LLC Takes $11.90 Million Position in Lantheus Holdings, Inc. $LNTH

Galvin Gaustad & Stein LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 145,352 shares of the medical equipment provider’s stock, valued at approximately $11,899,000.

A number of other hedge funds have also recently bought and sold shares of the company. Westfield Capital Management Co. LP boosted its position in Lantheus by 2.2% during the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock worth $155,101,000 after acquiring an additional 34,052 shares during the last quarter. Reinhart Partners LLC. raised its stake in shares of Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after acquiring an additional 197,719 shares during the period. Dimensional Fund Advisors LP increased its stake in Lantheus by 2.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after buying an additional 31,454 shares during the period. Swedbank AB increased its stake in Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after buying an additional 121,500 shares during the period. Finally, TD Asset Management Inc grew its holdings in Lantheus by 1,028.0% during the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock worth $66,623,000 after acquiring an additional 622,100 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LNTH. JMP Securities decreased their price target on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a report on Wednesday. TD Cowen dropped their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. Mizuho dropped their target price on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Finally, William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.50.

Insider Buying and Selling at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of Lantheus stock opened at $52.39 on Friday. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of 13.93 and a beta of 0.09. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $118.21. The firm has a fifty day simple moving average of $54.85 and a 200-day simple moving average of $75.05. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.